ERAS: the cashflow

MyFinsight

For the quarter ending 2025-09-30, ERAS had $4,087K increase in cash & cash equivalents over the period. -$21,664K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-30,612	-64,842
Depreciation and amortization	755	1,609
Stock-based compensation expense	5,965	13,111
In-process research and development expenses	2,000	7,500
Accretion on marketable securities, net	1,022	3,485
Prepaid expenses and other current and long-term assets	903	-516
Accounts payable	1,366	1,195
Accrued expenses and other current and long-term liabilities	1,190	-6,628
Operating lease assets and liabilities, net	397	1,062
Net cash used in operating activities	-21,658	-52,086
Purchases of marketable securities	41,540	67,204
Maturities of marketable securities	71,250	122,827
In-process research and development	4,000	5,500
Purchases of property and equipment	6	113
Net cash provided by (used in) investing activities	25,704	50,010
Proceeds from the exercise of stock options	41	76
Proceeds from issuance of common stock under the employee stock purchase plan	0	404
Net cash provided by financing activities	41	480
Net increase (decrease) in cash, cash equivalents and restricted cash	4,087	-1,596
Cash and cash equivalents at beginning of period	68,147	-
Cash and cash equivalents at end of period	70,638	-

Unit: Thousand (K) dollars